239 related articles for article (PubMed ID: 22408746)
1. TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.
Novitskiy SV; Pickup MW; Gorska AE; Owens P; Chytil A; Aakre M; Wu H; Shyr Y; Moses HL
Cancer Discov; 2011 Oct; 1(5):430-41. PubMed ID: 22408746
[TBL] [Abstract][Full Text] [Related]
2. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.
Li X; Sterling JA; Fan KH; Vessella RL; Shyr Y; Hayward SW; Matrisian LM; Bhowmick NA
Mol Cancer Res; 2012 Apr; 10(4):494-503. PubMed ID: 22290877
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.
Keklikoglou I; Koerner C; Schmidt C; Zhang JD; Heckmann D; Shavinskaya A; Allgayer H; Gückel B; Fehm T; Schneeweiss A; Sahin O; Wiemann S; Tschulena U
Oncogene; 2012 Sep; 31(37):4150-63. PubMed ID: 22158050
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-specific TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis.
Meng X; Vander Ark A; Lee P; Hostetter G; Bhowmick NA; Matrisian LM; Williams BO; Miranti CK; Li X
Oncogene; 2016 May; 35(18):2370-8. PubMed ID: 26279296
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta promotes Th17 cell development through inhibition of SOCS3.
Qin H; Wang L; Feng T; Elson CO; Niyongere SA; Lee SJ; Reynolds SL; Weaver CT; Roarty K; Serra R; Benveniste EN; Cong Y
J Immunol; 2009 Jul; 183(1):97-105. PubMed ID: 19535626
[TBL] [Abstract][Full Text] [Related]
7. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Cancer Res; 2007 May; 67(10):4869-77. PubMed ID: 17495323
[TBL] [Abstract][Full Text] [Related]
8. Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression.
Fang WB; Jokar I; Chytil A; Moses HL; Abel T; Cheng N
Clin Exp Metastasis; 2011 Apr; 28(4):351-66. PubMed ID: 21374085
[TBL] [Abstract][Full Text] [Related]
9. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
Matise LA; Palmer TD; Ashby WJ; Nashabi A; Chytil A; Aakre M; Pickup MW; Gorska AE; Zijlstra A; Moses HL
Breast Cancer Res; 2012 Jul; 14(4):R98. PubMed ID: 22748014
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.
Morris SM; Baek JY; Koszarek A; Kanngurn S; Knoblaugh SE; Grady WM
Hepatology; 2012 Jan; 55(1):121-31. PubMed ID: 21898503
[TBL] [Abstract][Full Text] [Related]
11. Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-beta signaling.
Upadhyay G; Yin Y; Yuan H; Li X; Derynck R; Glazer RI
Proc Natl Acad Sci U S A; 2011 May; 108(19):7820-5. PubMed ID: 21518866
[TBL] [Abstract][Full Text] [Related]
12. Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties.
Novitskiy SV; Pickup MW; Chytil A; Polosukhina D; Owens P; Moses HL
J Leukoc Biol; 2012 Sep; 92(3):641-51. PubMed ID: 22685318
[TBL] [Abstract][Full Text] [Related]
13. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL
Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643
[TBL] [Abstract][Full Text] [Related]
14. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Cheng N; Bhowmick NA; Chytil A; Gorksa AE; Brown KA; Muraoka R; Arteaga CL; Neilson EG; Hayward SW; Moses HL
Oncogene; 2005 Jul; 24(32):5053-68. PubMed ID: 15856015
[TBL] [Abstract][Full Text] [Related]
15. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.
Pickup MW; Laklai H; Acerbi I; Owens P; Gorska AE; Chytil A; Aakre M; Weaver VM; Moses HL
Cancer Res; 2013 Sep; 73(17):5336-46. PubMed ID: 23856251
[TBL] [Abstract][Full Text] [Related]
16. Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptor.
Borczuk AC; Sole M; Lu P; Chen J; Wilgus ML; Friedman RA; Albelda SM; Powell CA
Cancer Res; 2011 Nov; 71(21):6665-75. PubMed ID: 21911454
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.
Bierie B; Chung CH; Parker JS; Stover DG; Cheng N; Chytil A; Aakre M; Shyr Y; Moses HL
J Clin Invest; 2009 Jun; 119(6):1571-82. PubMed ID: 19451693
[TBL] [Abstract][Full Text] [Related]
19. Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.
Ryzhov SV; Pickup MW; Chytil A; Gorska AE; Zhang Q; Owens P; Feoktistov I; Moses HL; Novitskiy SV
J Immunol; 2014 Sep; 193(6):3155-64. PubMed ID: 25127858
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-specific disruption of TGF-β receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity.
Ramalingam R; Larmonier CB; Thurston RD; Midura-Kiela MT; Zheng SG; Ghishan FK; Kiela PR
J Immunol; 2012 Oct; 189(8):3878-93. PubMed ID: 22972928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
